Track topics on Twitter Track topics that are important to you
New headquarters strengthen drug discovery services and translational research, and generate new employment opportunities in Scotland.Glasgow, UK. 10th August 2017: REPROCELL Europe Ltd (REPROCELL), a leading provider of products and services for research in stem cells, drug discovery, human tissues and 3D cell culture and a member of the REPROCELL Group, has opened its European headquarters in Glasgow, UK. The REPROCELL Centre for Predictive Drug Discovery at West of Scotland Science Park was inaugurated by Scotland’s First Minister, Nicola Sturgeon. The new headquarters will enable the company to strengthen its pharmaceutical industry-targeted drug discovery services and translational research, and generate new employment opportunities in Scotland. The company’s relocation to the West of Scotland Science Park was supported by £150,000 of Regional Selective Assistance from Scottish Enterprise in December 2016. Since then, REPROCELL has invested a further £630,000 to expand its European headquarters and develop its product and service offering.REPROCELL has expertise in the development of predictive assays using stem cells, 3D tissue models and fresh human tissues, which offer the pharmaceutical industry novel tools for investigating the safety and efficacy of new drug candidates early in the drug discovery process. The Centre for Predictive Drug Discovery will allow the company to continue to develop these lines of business by growing its Glasgow-based workforce and expand operations to focus on the launch of new services. Commenting on the company’s new Scottish headquarters Nicola Sturgeon, First Minister of Scotland said: “Life sciences is an exciting and developing growth sector for Scotland’s economy and it is testament to confidence in the sector that REPROCELL has decided to base its European operations here. The jobs that are being created and safeguarded will provide significant benefit to the surrounding area and I am looking forward to seeing the company go from strength to strength in the future.”Dr David Bunton, CEO of REPROCELL Europe Ltd said: “Scottish Enterprise has worked closely with the company in Scotland, Europe, US and Japan to provide business support. This has included work from SDI field colleagues in Japan and across Europe to help identify potential customers, as well as tailored company support on the ground in Scotland to look at new market opportunities globally and extend existing testing services.”Rhona Allison, Company Growth Senior Director at Scottish Enterprise, said: “REPROCELL’s new expertise in stem-cell reprogramming and 3D cell culture, together with its world class facilities are a further and significant boost to Scotland’s growing life sciences capabilities. The company’s confidence in Scotland is testament to the country’s global reputation in the sector and we look forward to continuing to work closely with the REPROCELL team to help them realise their growth ambitions.”NEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Track and monitor developments in stem cell research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry. BioPort...
Types of Cell Culture Open https://www.youtube.com/watch?v=WGKoJRNKADY to view video on cell culture basics. Four catagories of cell culture techniques are listed below: Adherent cells Cells shown to require attachment for growth are sa...